Nonalcoholic Fatty Liver Disease

Disease State Hub

Polls

Cardiometabolic risk

07/02/2020

It has been unclear whether nonalcoholic fatty liver disease is directly related to cardiovascular disease or whether this relationship is confounded by metabolic factors of NAFLD and CVD. What do you...

07/02/2020

Research Summaries

FDA Alert

FDA Approves First Treatment for Adults With MASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

research summary

CVD Risk Is Increased in Patients with HIV and NAFLD, Liver Fibrosis

04/26/2023

Leigh Precopio

To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...

04/26/2023

Obesity

High Prevalence of NAFLD, NASH in Overweight, Obese Populations

12/05/2022

Researchers identified the prevalence of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in individuals who are overweight or obese. ...

12/05/2022

diagnosis and management

AHA Releases First Scientific Statement on NAFLD, ASCVD

04/28/2022

Nonalcoholic fatty liver disease is estimated to occur in 1 in 4 adults worldwide but understanding of the disease and associated complications is lacking. The American Heart Association recently released a...

04/28/2022

Nonalcoholic Fatty Liver Disease

Fecal Microbiota Transplantation Is Examined for Treating NAFLD

07/31/2020

While it has proven safe and effective for treating recurrent or refractory Clostridiodes difficile infections in patients with inflammatory bowel disease, fecal microbiota transplantation may also improve...

07/31/2020

October 2024

Current Issue

October 2024

Volume 64

Issue 9